All these findings led to our conclusion that the effects of COX-2 inhibitors on pancreatic cancer cell invasiveness are primarily related to COX-2/PGE2  pathway, though the possibility of other mechanisms' involvement can hardly be ruled out. Here, PTGS2 is linked to familial pancreatic carcinoma.